Tenax Therapeutics is focused on identifying, developing and commercializing products for the critical care market.In the U.S. alone, more than five million hospitalized patients are treated in an intensive care setting annually according to the Society of Critical Medicine.
The LEVO-CTS trial results were presented on
Sunday, March 19, 2017, at the
American College of Cardiology
66th Annual Scientific Session in Washington, D.C.
Focus on Critical CareGiven the high mortality, morbidity, and costs associated with the treatment of many intensive care patients, we believe that there is a substantial opportunity to add value for patients, physicians, hospitals, and ultimately shareholders.
May 16 2017 Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission Apr 05 2017 Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update Mar 21 2017 Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update